Norethindrone/Ethinyl Estradiol

DRUG5 trials

Sponsors

Warner Chilcott, Mutual Pharmaceutical Company, Inc., Genentech, Inc., Teva Pharmaceuticals USA

Conditions

BioequivalenceContraceptionHealthyPharmacokineticsSolid Cancers

Phase 1

A Pharmacokinetic Study of Colchicine With an Oral Contraceptive

CompletedNCT01040845

Mutual Pharmaceutical Company, Inc.Pharmacokinetics

Start: 2007-08-31End: 2008-02-29Updated: 2010-01-05

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

CompletedNCT01209143

Genentech, Inc.Solid Cancers

Start: 2010-11-30End: 2012-03-31Updated: 2015-06-29

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

CompletedNCT01340625

Teva Pharmaceuticals USABioequivalence

Start: 2006-12-31End: 2007-01-31Updated: 2011-05-25

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

CompletedNCT01344369

Teva Pharmaceuticals USAHealthy

Start: 2008-08-31End: 2008-09-30Updated: 2011-05-30

Phase 3

Study of Safety and Efficacy of an Oral Contraceptive

CompletedNCT00477633

Warner ChilcottContraception

Start: 2007-06-30End: 2009-02-28Updated: 2013-04-22